

References

1. Abbott, K., "Defining the Extraterritorial Reach of American Export Controls: Congress as Catalyst," *Cornell International Law Journal* 17:81-145, 1984.
2. Abbott, K.W., "Collective Goods, Mobile Resources, and Extraterritorial Trade Controls," *Law and Contemporary Problems* 50(3): 117-152, 1987.
3. Abraham, M., "Blowing the Whistle on Hazardous Exports," *Information Development* 2(1):33-37, 1986.
4. Abraham, M., Head, Information and Research, International Organization of Consumers Unions, Penang, Malaysia, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Mar. 9, 1991.
5. Ahmad, S.R., *Bitter Facts About Drugs* (Karachi, Pakistan: Shadeb Printers, 1992).
6. American Law Institute, *Restatement (Third) of the Law: The Foreign Relations Law of the United States* (St. Paul, MN: American Law Institute Publishers, 1987).
7. American Medical Association, *Drug Evaluations* (Chicago, IL: American Medical Association, 1986).
8. American Society of Hospital Pharmacists, *American Hospital Formulary Service* (Bethesda, MD: American Society of Hospital Pharmacists, various years).
9. Arnold, R., Executive Vice President, International Federation of Pharmaceutical Manufacturers Associations, Geneva, Switzerland, letter to Dr. Peter Mansfield, Secretary, MaLAM, Adelaide, Australia, Jan. 22, 1990, reprinted in *MaLAM Newsletter*, May 1990.
10. Association of British Pharmaceutical Industry, *ABPI Data Sheet Compendium* (London, UK: Datapharm Publications, Ltd., 1992).
11. Baade, H. W., "Legal Effects of Code of Conduct for MNEs," *Legal Problems of Codes of Conduct for Multinational Enterprises*, N. Horn [ed.] (The Netherlands: Kluwer-Deventer, 1980).
12. Balasubramaniam, K., *Global Marketing of Pharmaceuticals: Prescription for Disaster* (Penang, Malaysia: International Organization of Consumers Unions, 1988).
13. Balasubramaniam, K., *Policies and Strategies on Drug Pricing Regulations: International Experiences* (Penang, Malaysia: International Organization of Consumers Unions, 1988).
14. Balasubramaniam, K., *Policy Options in Pharmaceutical Patents for Developing Asian Countries* (Penang, Malaysia: International Organization of Consumers Unions, 1988).
15. Balasubramaniam, K., *The Rational Use of Drugs: A Universal Concept* (Penang, Malaysia: International Organization of Consumers Unions, 1988).
16. Banotti, M., "Report on the Export of Pharmaceutical Products From the European Community to the Countries of the Third World," for the Committee on the Environment, Public Health and Consumer Protection, European Parliament, Apr. 23, 1986.
17. Beaver, L. B., Health Scientist Administrator, International Affairs Staff, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, memorandum to Office of Technology Assessment, U.S. Congress, Washington, DC, Jan. 18, 1991.

18. Beppu, H., "Japan: Database of Inactive Ingredients," *Lancet* 1(8800):983, 1992.
19. Blumberg, P. I., "The Corporate Entity in an Era of Multinational Corporations," *Delaware Journal of Corporate Law* 15:283-374, 1990.
20. Boddewyn, J. J., *Medicine Advertising Regulation and Self-Regulation in 54 Countries* (New York, NY: International Advertising Association, Inc. 1985) reprinted in World Health Organization, *Report on the WHO Survey On "Ethical Criteria For Drug Promotion"* (Geneva, Switzerland: World Health Organization, 1987).
21. Boddewyn, J. J., "Comments on Hamilton and Whinnett's Article on Breastmilk Substitutes Codes in JCP, 10, 1987/2," *Journal of Consumer Policy* 11:235-239, 1988.
22. Bolton, J. R., Assistant Secretary for International Organization Affairs, U.S. Department of State, Statement, *The Status of the United Nations Code of Conduct on Transnational Corporations*, hearing before the Subcommittee on International Economic Policy, Trade, Oceans and Environment, Committee on Foreign Relations, U.S. Senate, Oct. 11, 1990, Serial No. 101-1014 (Washington, DC: U.S. Government Printing Office, 1990).
23. Bombelles, T., Assistant Vice President, International, Pharmaceutical Manufacturers Association; Noone, M., Manager, Medical Regulatory Affairs, Eli Lilly; Roylance, P., Executive Medical Director, Human Health Division, Merck & Co., Ruark, R., Vice President, Administration, Human Health Division, Merck & Co.; Schwob, M., Senior Manager, World Wide Medical Affairs, Bristol-Myers Squibb Co., Meeting at the Pharmaceutical Manufacturers Association, Washington DC, Dec. 13, 1991.
24. Boni, A. F., Pharmaceutical/Health Program Specialist, Office of Health, Health Services Division, U.S. Agency for International Development, Washington, DC, personal communication, July 1992.
25. Borek, T., Assistant Legal Advisor, Economic and Business Affairs, U.S. Department of State, Washington DC, personal communication, May 1, 1992.
26. Boston College International & Comparative Law Review, "Foreign Corrupt Practices Act of 1977: An Analysis of its Impact and Future," *Boston College International & Comparative Law Review* 5:405-430, 1982.
27. Bowman, C., "Extraterritorial Application of United States Laws: *Star Kist Foods, Inc. v. P.J. Rhodes and Co.*," *Arizona Journal of International and Comparative Law* 1987 annual, 164-168, 1987.
28. Braunwald, E., Fauci, A., Isselbacher, K.J., et al. (eds.), *Harrison's Principles of Internal Medicine* (New York, NY: McGraw-Hill, 1987).
29. Bristol-Myers Squibb Co., Annual Report, Filing With the U.S. Securities and Exchange Commission, Washington, DC, 1989.
30. Bruchhausen, F. von, *Pharmakotherapie, klinische Pharmakologie/N: ein Lehrbuch für Studierende und ein Ratgeber für Ärzte* (Stuttgart, Germany: Fischer, 1986).
31. Bryant, W.R. Jr., Acting Chief, Emergency Operations Branch, Division of Emergency and Epidemiology Operations, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, July 24, 1991.
32. Budashewitz, P., Special Programs Desk Officer, International Affairs Staff, Office of Health Affairs, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, Aug. 27, 1992.
33. Chetley, A., *Cleared for Export (The Hague, The Netherlands: Coalition Against Dangerous Exports, 1985)*.
34. Chetley, A., "Not Good Enough For Us But Fit For Them—An Examination of the Chemical and Pharmaceutical Export Trades," *Journal of Consumer Policy* 9:155-180, 1986.
35. Chetley, A., *Antibiotics: The Wrong Drugs for Diarrhoea* (Amsterdam, The Netherlands: Health Action International, 1987).
36. Chetley, A., *Peddling Placebos: An Analysis of Cold and Cough Remedies* (Amsterdam, The Netherlands: Health Action International-Europe, 1989).
37. Chetley, A., *A Healthy Business? World Health and the Pharmaceutical Industry* (London, UK: Zed Books, Ltd., 1990).
38. Chetley, A., and Gilbert, D., *Problem Drugs* (Penang, Malaysia: International Organization of Consumers Unions, 1986).
39. Chetley, A., and Mintzes, B. (eds.), *Promoting Health or Pushing Drugs* (Amsterdam, The Netherlands: Drukgood, 1992).

40. Chidomere, E. C., *Drug Regulation in African Countries* (Lagos, Nigeria: Pharmanews Publishers, 1982).
41. Clark, E., *The Want Makers: Lifting the Lid Off the World Advertising Industry: How They Make You Buy* (London, UK: Hodder & Stoughton, 1988).
42. Commonwealth Pharmaceutical Conference Working Group, "Product Registration in Developing Countries," *Pharmaceutical Journal* 238:469-70, 1987.
43. Connecticut Journal of International Law, "The Domestic and Extraterritorial Application of United States Employment Discrimination Law to Multinational Corporations," *Connecticut Journal of International Law* 4: 145-183, 1988.
44. Coppinger, P., Deputy Associate Commissioner for Planning and Evaluation, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, May 1, 1992.
45. Corr, B., Chief Counsel, Subcommittee on Antitrust, Monopolies and Business Rights, Committee on the Judiciary, Senate, U.S. Congress, Washington, DC, personal communications, Dec. 21, 1991 and July 14, 1992.
46. Covington, T. R., DiPalma, J. R., Hussar, D. A., et al. (eds.), *Drug Facts and Comparisons* (S, Louis, MO: J.B. Lippincott Co., 1986).
47. De Schaepdryver, A. F., (cd.), *Manual for Rural Health Workers: Diagnosis and Treatment With Essential Drugs* (Ghent, Belgium: Heymans Foundation, 1991).
48. DelPonte, K. G., "Formulating Customary International Law: An Examination of the WHO International Code of Marketing of Breast Milk Substitutes," *Boston College International & Comparative Law Review* 5:377-403, 1982.
49. Department of State Bulletin, Annex to the "Declaration of 21st June, 1976 by Governments of OECD Member Countries on International Investment and Multinational Enterprises, Guidelines for Multinational Enterprises," *Department of State Bulletin* 75(1934):84-87, 1976.
50. *Dominicus Americana Bohio v. Gulf & Western Industries, Inc.*, 473 F. Supp. 680, 687 (S. D.N.Y. 1979).
51. Dukes, M. N. G., "The Regulation of Drugs: Worlds of Difference," *international Journal of Technology Assessment in Health Care* 2:629-636, 1986.
52. Dunne, J. F., Director, WHO Drug Management Program, World Health Organization, Geneva, Switzerland, Letter to Marjory Dam, Information and External Relations Officer, Pan American Health Organization, Washington, DC, Dec. 3, 1990.
53. Dunne, M., Flood, M., Herxheimer, A. (eds.), *Clioquinol: Availability and Instructions for Use* (London, UK: International Organization of Consumers Unions, 1975).
54. Emmanuel, M., "Communicating Information on Health and Drugs," *HAI News* 50:1-2, 11-12, 1990.
55. *E.E.O.C. v. Arabian American Oil Company; Ali Boureslan v. Arabian American Oil Company* 111 S. Ct. 1227; 113 L. Ed. 2d 274; 1991.
56. Eshelman, R., Compliance Officer, OTC Drug Compliance Branch, Division of Drug Labeling and Compliance, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, personal communication, February 1992.
57. Essential Drugs Monitor, "Cooperative Programme on Pharmaceuticals," *Essential Drugs Monitor* 8:13, 1989.
58. *Eurim-Pharm GmbH v. Pfizer Inc.*, 593 F. Supp. 110 (S. D.N.Y. 1984).
59. European Communities, "European Communities: Comments on the U.S. Regulations Governing Trade With the U. S. S.R.," *International Legal Materials* 21(4):891-905, 1982.
60. Fay, R., Division of Drug Labeling and Compliance, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, personal communication, Apr. 2, 1991.
61. Fazal, A., "The Right Pharmaceuticals at the Right Prices: Consumer Perspectives," *Pharmaceuticals & Health in the Third World* S. Patel (cd,) (Elmsford, NY: Pergamon Press, 1983).
62. The Federal Congress of Development Action Groups (BUKO), *Pharmakampagne, Hoechst -- a Cause of Illness? The Pharmabusiness in the Third World* (Bielfeld, Germany: Druckwerkstatt im Umweltzentrum, 1987).
63. The Federal Congress of Development Action Groups (BUKO), *Drugs and Primary Health*

- Care (Amsterdam, The Netherlands: Health Action International, 1991).
64. The Federal Congress of Development Action Groups (BUKO), "The Pharma-Bnef," *Update Europe* 1(1):6, 1991.
 65. Franko, L. G., "New Forms of Investment in Developing Countries by US Companies: A Five Industry Comparison," *Columbia Journal of World Business* 22(2):39-56, 1987.
 66. Fremantle, A., and Katz, S., "The Foreign Corrupt Practices Act Amendments of 1988," *The International Lawyer* 5(23):755-767, 1989.
 67. Freres des Hommes, *Le Medicament au Maghreb et en Afrique Noire Francophone* (Grenoble, France: Presses Universitaires de Grenoble, 1989).
 68. Gangopadhyay, S. K., "Economic and Technological Co-Operation in the Pharmaceutical Industry," paper presented at "The Interregional Meeting on Co-operation among Developing Countries for the Development of the Pharmaceutical Industry," conference sponsored by UNIDO, New Delhi, India, Mar, 19-22, 1990.
 69. Gartner, E. C., "Regulating Export of Unapproved Drugs: An Examination of the Drug Export Amendments Act of 1986," *Columbia Human Rights Law Review* 19(1):97-121, 1987.
 70. Gazeta Mercantil, "As Grandes Compras do Ache," *Balanceo Anual 1989: Gazeta Mercantil* (Sao Paulo, Brazil: Gazeta Mercantil, 1989) cited in reference 206,
 71. Geerling, H., Hardon, A., le Grand, A., et al., *The Provision and Use of Drugs in Developing Countries* (Amsterdam, The Netherlands: Het Spinhuis, 1991).
 72. George Washington Journal of International Law & Economics, "The Ethics and Economics of Unapproved New Drug Export," *George Washington Journal of International Law & Economics* 21 :315-345, 1987.
 73. Gerber, D. J., "Beyond Balancing: International Law Restraints on the Reach of National Laws," *Yale Journal of International Law*, 10(1): 185-221, 1984,
 74. Gleckman, H., Research Officer, United Nations Centre on Transnational Corporations, United Nations, New York, NY, personal communications, June 1992, January 1993.
 75. Goodman, A., Gilman, L., Murad, F., et al. (eds.), *The Pharmacological Basis of Therapeutics* (New York, NY: Macmillan, 1985).
 76. Gotlieb A. E., "Extraterritoriality: A Canadian Perspective," *Northwestern Journal of International Law & Business* 5(3):449-461, 1983.
 77. Greenhalgh, T., "Drug Marketing in the Third World: Beneath the Cosmetic Reforms," *Lancet* 1(8493):1318-1320, 1986.
 78. Greenwood, J., *Marketing Medicines* (London, UK: Remit Consultants, 1991) cited in reference 39.
 79. Gustafsson, L., and Wide, K., "Marketing of Obsolete Antibiotics in Central America," *Lancet* 1(8210):31-33, 1981.
 80. Hadari, Y., "The Structure of the Private Multinational Enterprise," *Michigan Law Review* 71:731-804, 1973.
 81. Hartog, R., and Schulte-Sasse, H., *German and Swiss Drug Supplies to the Third World: Survey and Evaluation of Pharmacological Rationality* (Zurich, Switzerland: HAI-Europe, Berne Declaration Group, BUKO Pharma-Kampagne, 1990).
 82. Harvard Law Review, "Constructing the State Extraterritorially: Jurisdictional Discourse, the National Interest and Translational Norms," *Harvard Law Review* 103: 1273-1305, 1990.
 83. Hatch, O. G., "The Future Direction of the Food and Drug Administration," *Food Drug Cosmetic Law Journal* 46(1):15-20, 1988,
 84. Health Action International, *Draft International Code on Pharmaceuticals* (Amsterdam, The Netherlands: Health Action International, 1982),
 85. Health Action International, "Fewer Drugs, Better Therapy: Learning From the Third World?" *HAI News* 38:6, 1987,
 86. Health Action International, *Controlling Drug Promotion* (Amsterdam, The Netherlands: Health Action International, 1988).
 87. Health Action International, "Antidiarrhoeals in Latin America," *HAI News* 58:5, 1991.
 88. Health Action International, *10 Years HAI (Penang, Malaysia: International Organization of Consumers Unions, 1991).*
 89. Health Action International, *The Impact of WHO Ethical Criteria for Medicinal Drug Promotion: A Study by Health Action International (HAI)* (Amsterdam, The Netherlands: Health Action International, undated).
 90. Health Horizons, "The IFPMA Code: How It Works and How It is Working," *Health Horizons* 2:18-19, 1987.
 91. Health Horizons, "The International Industry Discusses Marketing Standards," *Health Horizons*, May 1988.

92. Hein, J., "The World's Multinationals: A Global Challenge," *Information Bulletin No. 84* (New York, NY: The Conference Board, 1981).
93. Herxheimer, A., Stalsby, C., and Westerholm, B., *Advertisements for Medicines in Medical Journals: A Collaborative International Study*, typescript (Stockholm, Sweden: National Corporation of Pharmacies, 1991).
94. *Hilton v. Guyot* 159 U.S. 113, 163-164 (1895).
95. Ho, J., Asian Pacific Desk Officer, International Affairs Staff, Office of Health Affairs, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, Rockville, MD, personal communication, July 24, 1991.
96. Hodges, D., Manager, International Regulatory Support Services, The Upjohn Co., Kalamazoo, MI, personal communication, July 15, 1992.
97. Hodgkin, C., Coordinator, HAI Europe, Amsterdam, The Netherlands, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Aug. 27, 1992.
98. Horn, N. (cd.), *Legal Problems of Codes of Conduct for Multinational Enterprises* (The Netherlands: Kluwer-Deventer, 1980).
99. Houston Journal of International Law, "Hands Across the Water: Should Title VII of the Civil Rights Act of 1964 Have Extraterritorial Application?" *Houston Journal of international Law* 12:125-142, 1989.
100. Hutt, P. B., and Merrill, R. A., *Food and Drug Law—Cases and Materials* (2nd cd.) (Westbury, NY: The Foundation Press, 1991).
101. Index of Medical Specialties, *Mercado Farmaceutica Brasil* (Switzerland: Index of Medical Specialties, 1989) cited in reference 206.
102. International Barometer, "Worldwide Activist Network Keeps Pace With Pharmaceutical Industry-wherever It Is," *International Barometer* 2(10):1-4, 1987.
103. International Barometer, "Pharmaceutical Industry, Police Thyself, Say HAI Leaders," *International Barometer* 2(10):S1-S3, 1987.
104. International Chamber of Commerce, Committee on the Extraterritorial Application of National Law, *The International Application of National Laws* (Boston, MA: Deventer Publishers, 1987).
105. International Court of Justice Statute Article 38(1)(b), cited in reference 48.
106. International Federation of Pharmaceutical Manufacturers Associations, *Legal and Practical Requirements for the Registration of Drugs (Medicinal Products) for Human Use* (Zurich, Switzerland: International Federation of Pharmaceutical Manufacturers Associations, 1987).
107. International Federation of Pharmaceutical Manufacturers Associations, *Compendium on Regulation of Pharmaceuticals for Human Use* (Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations, 1989).
108. International Federation of Pharmaceutical Manufacturers Associations, *Pharmaceutical Industry Projects in the Third World* (Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations, 1990).
109. International Federation of Pharmaceutical Manufacturers Associations, *Tenth Status Report on the IFPMA Code of Pharmaceutical Marketing Practices* (Geneva Switzerland: International Federation of Pharmaceutical Manufacturers Associations, 1990).
110. International Federation of Pharmaceutical Manufacturers Associations, *The IFPMA Code of Pharmaceutical Marketing Practices—The First Years 1981-1991* (Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations, undated).
111. International Federation of Pharmaceutical Manufacturers Associations, *IFPMA Code of Pharmaceutical Marketing Practices* (Geneva, Switzerland: International Federation of Pharmaceutical Manufacturers Associations, undated).
112. International Network for Rational Use of Drugs, *INRUD News* 1(1), 1990.
113. International Network for Rational Use of Drugs, "INRUD Update," *INRUD News* 2(2): 1,20, 1991,
114. International Network for Rational Use of Drugs, "INRUD Bibliography," *INRUD News* 2(2):8, 1992,
115. International Network for Rational Use of Drugs, "SPECIAL Section: Methods for INRUD Indicators," *INRUD News* 2(2):9-12, 1992.
116. International Office of Consumers Unions, "Chloramphenicol: Recommended Used and Warnings," *International Consumer*, 14(3):11-15, 1973, cited in references 34 and 61.
117. International Organization of Consumers Unions, Consumer Interpol Coordinator, *Consumer Interpol—Fighting Hazardous Products and Technologies* (Penang, Malaysia: International Organization of Consumers Unions, undated).

118. International Organization of Consumers Unions, *Anabolic Steroids: Availability and Marketing* (Penang, Malaysia: International Organization of Consumers Unions, 1983).
119. Janssen, W. F., "Outline of the History of U.S. Drug Regulation and Labeling," *Food Drug Cosmetic Law Journal* 36:420-441, 1981.
120. Jelliffe D., Head, Division of Population, Family, and International Health, University of California, Los Angeles, CA, Statement, *Marketing and Promotion of Breastmilk Substitutes in Developing Nations*, 1978, hearings before the Subcommittee on Health and Scientific Research of the Committee on Human Resources, U.S. Senate, May 28, 1978, Committee Print (Washington, DC: Government Printing Office, 1978).
121. Johnson, Keith, "Defining Medically Accepted But FDA-Unapproved Uses of Drugs: Implications for Practice and Reimbursement," unpublished paper presented at conference sponsored by the American College of Clinical Pharmacology, Las Vegas, Nevada, December 1990.
122. Journal of Criminal Law & Criminology, "Amending the Foreign Corrupt Practices Act of 1977: A Step Toward Clarification and Consolidation," *Journal of Criminal Law & Criminology* 73:1740-1773, 1982.
123. Kessler, D. A., and Pines, W. L., "The Federal Regulation of Prescription Drug Advertising and Promotion," *Journal of the American Medical Association* 264(18):2409-2414, 1990.
124. Kirkland, R. I., "Entering a New Age of Boundless Competition," *Fortune* 117(6):40-48, 1988.
125. Kline, J. M., *International Codes and Multi-national Business* (Westport, CT: Quorum Books, 1985).
126. Laetz, T., and Silberman, G., "Reimbursement Policies Constrain the Practice of Oncology," *Journal of the American Medical Association* 266(21):2996-2999, 1991.
127. Laing, R. O., "Rational Drug Use: An Unsolved Problem," *Tropical Doctor* 20:101-103, 1990.
128. Laing, R. O., "International Network for the Rational Use of Drugs (INRUD)," *Tropical Doctor* 20:133-134, 1990.
129. Laing, R. O., Drug Use Coordinator, Management Sciences for Health, Boston, MA, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Sept. 11, 1992.
130. **Lancet**, "International Drug Marketing Code," *Lancet* 1(8592):988, 1988.
131. **Lancet**, "WHO Collaborating Centre on Drug Information," *Lancet* 1(8592):988, 1988.
132. Lasagna, L., and Werko, L., "International Differences in Drug Regulation Philosophy," *International Journal of Technology Assessment in Health Care* 2:615-618, 1986.
133. Law and Contemporary Problems, "Extra-territorial Subsidiary Jurisdiction," *Law and Contemporary Problems* 50(3):71-93, 1987.
134. Ledogar, R. J., *Hungry for Profits* (New York, NY: IODC, 1975).
135. London School of Hygiene and Koninklijk Instituut voor de Tropen, *An Evaluation of WHO's Action Programme on Essential Drugs*, Submitted to the Management Advisory Committee, The Action Programme on Essential Drugs, World Health Organization, vols. I-III (Amsterdam, The Netherlands: Axel Nielsen & Sons A/S, 1989).
136. Maier, H., "Extraterritorial Jurisdiction at a Crossroads: An Intersection Between Public and Private International Law," *The American Journal of International Law* 76:280-320, 1982.
137. Marndani, M., and Walker, G., *Essential Drugs and Developing Countries, A Review and Selected Annotated Bibliography* (London, UK: Evaluation and Planning Centre for Health Care, London School of Hygiene and Tropical Medicine, 1985).
138. *Mannington Mills, Inc. v. Congoleum Corp.*, 595 F.2d 1287 (3rd Cir. 1979).
139. Mansfield, P., Secretary, MaLAM, Adelaide, Australia, letter to Dr. Richard Arnold, Executive Vice President, International Federation of Pharmaceutical Manufacturers Associations, Apr. 9, 1990, reprinted in *MaLAM Newsletter*, May 1990.
140. Mathur, R. S., "Industrial Drug Policy—The Indian Experience," paper presented at the Interregional Meeting on Co-operation Among Developing Countries for the Development of the Pharmaceutical Industry, New Delhi, India, conference sponsored by UNIDO, Mar. 19-22, 1990.
141. *William McGlinchy, Dan-de Products Corporation, v. Shell Chemical Corporation*, 845 F.2d 802 (9th Cir. 1987).
142. Medawar, C., *Insult or Injury? An Enquiry into the Marketing and Advertising of British Food and Drug Products in the Third World* (London, UK: Social Audit, Ltd., 1979).

143. Medawar, C., *Drug Disinformation: What British and Multinational Drug Companies Tell Doctors About Their Products, At Home and Abroad* (London, UK: Social Audit, Ltd., 1980).
144. Medawar, C., *The Wrong Kind of Medicine?* (London, UK: Consumer's Association and Social Audit, Ltd., 1984).
145. Medawar, C., "International Regulation of the Supply and Use of Pharmaceuticals," *Development Dialogue* 2:15-37, 1985.
146. Medawar, C., *Drugs and World Health* (Penang, Malaysia: International Organization of Consumers Unions, 1989).
147. Medawar, C., *Power and Dependence* (London, UK: Social Audit, Ltd., 1992).
148. Medawar, C., and Freese, B., *Drug Diplomacy: Decoding the Conduct of a Multinational Pharmaceutical Company and the Failure of a Western Reined for the Third World* (London, UK: Social Audit, Ltd., 1982).
149. Medawar, C., Social Audit, *One Drug At A Time: A Report on the Limitations of Fixed-Rate Combination Drugs* (Penang, Malaysia: International Organization of Consumers Unions, 1984).
150. *Medical Bulletin* 22(1): 1992.
151. Medical Economics Co., *Physicians' Desk Reference* (Montvale, NJ: Medical Economics Co., 1987, 1988, 1989, 1990, 1991).
152. Medical Economics Co., *Physicians' Desk Reference for Nonprescription Drugs* (Oradell, NJ: Medical Economics Co., 1985, 1987, 1991).
153. Medical Lobby for Appropriate Marketing (MaLAM), "MaLAM's Origins," *MaLAM Newsletter* December 1988.
154. Melrose, D., *Bitter Pills: Medicines and the Third World Poor* (Oxford, UK: OXFAM, 1983).
155. Merck & Co., Inc., Annual Report, Filing With the U.S. Securities and Exchange Commission, Washington, DC, 1989.
156. Micklitz, H.-W., "EC Regulation of the Export of Dangerous Pharmaceuticals to Third World Countries: Some Prospects," *Journal of Consumer Policy* 11:29-53, 1988.
157. Millstein, L. G., "Drug Product Labeling," *New Drug Approval Process: Clinical and Regulatory Management*, R.A. Guarino (ed.) (New York, NY: Marcel Dekker, Inc., 1987).
158. Moertel, C., "Off-label Drug Use for Cancer Therapy and National Health Care Priorities," *Journal of the American Medical Association* 266(21):3031-3032, 1991.
159. Moore, K., University of Southern California, School of Pharmacy, Los Angeles, CA, "Background Paper—Labeling of Pharmaceuticals," unpublished paper, 1983.
160. Mossinghoff, G. J., President, Pharmaceutical Manufacturers Association, Statement, *Advertising, Marketing and Promotional Practices of the Pharmaceutical Industry*, hearing before the Committee on Labor and Human Resources, U.S. Senate, Dec. 11-12, 1991, Serial No. 101-1217 (Washington, DC: U.S. Government Printing Office, 1991).
161. Moyer, E. Jr., and Mabry, L., "Export Controls as Instruments of Foreign Policy: The History, the Legal Issues and Policy Lessons of Three Recent Cases," *Law and Policy in International Business* 15(1):1-179, 1983.
162. Moyer, E. Jr., Mabry, L., and Abbott, K., "Defining the Extraterritorial Reach of American Export Controls: Congress as Catalyst," *Cornell International Law Journal* 17:81-145, 1984.
163. Muller, M., *The Health of Nations: A North-South Investigation* (London, UK: Faber & Faber, 1982).
164. National Board of Health and Welfare Department of Drugs, Sweden, "Proceedings of the Third International Conference of Drug Regulatory Authorities," conference co-sponsored by the Swedish National Board of Health and Welfare and the World Health Organization, Stockholm, Sweden, June 10-15, 1984.
165. National Council for International Health, *Pharmaceuticals and Developing Countries—A Dialogue for Constructive Action* (Washington, DC: National Council for International Health, 1982).
166. Nightingale, S. L., "Domestic and International Responsibilities of the U.S. Food and Drug Administration," speech presented at The Second U.S.-Japan Healthcare Symposium, Atlanta, Georgia, Oct. 11, 1990.
167. Nightingale, S. L., "Unlabeled Uses of Approved Drugs," *Drug Information Journal* 26: 141-147, 1992.
168. Nightingale, S. L., Associate Commissioner for Health Affairs, Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Sept. 4, 1992.
169. Oakly, G. P., "The Neurotoxicity of the Halogenated Hydroxyquinolines," *Journal of the*

- American Medical Association* 225:395-7, 1973 cited in reference 53.
170. O'Reilly, J.T., *Regulatory Manual Series: Food and Drug Administration* (Colorado Springs, CO: **Shepard's/McGraw-Hill, Inc.**, 1990).
 171. Osifo, N. G., "Overpromotion of Drugs in International Product Package Inserts," *Tropical Doctor* 13:5-8, 1983.
 172. **Oyebode B.A.**, "International Regulation of the Multinational Corporation: A Look at Some Recent Proposals," *Black Law Journal* 5(2):23 1-248, 1977.
 173. **Paralos Medicos (PLM), Centro America Dominicana (CAD)** (Colombia: Editorial **para los Medicos, S.A.**, various years).
 174. **Patel, S. R.**, "Towards a New International Pharmaceutical Order," *HAI News* 39:1-3, 1988.
 175. Paul, J. R., "Comity in International Law," *Harvard International Law Journal* 32(1):1-80, 1991.
 176. Pfizer Inc., Annual Report, Filing With the U.S. Securities and Exchange Commission, Washington, DC, 1989.
 177. Pharmaceutical Manufacturers Association, 1989-1991 *Annual Survey Report* (Washington, DC: Pharmaceutical Manufacturers Association, 1991).
 178. Pharmaceutical Manufacturers Association, *Statistical Fact Book* (Washington, DC: Pharmaceutical Manufacturers Association, 1991).
 179. **Poolthup, P.**, First Secretary, Royal Thai Embassy, Washington, DC, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Sept. 10, 1992.
 180. Post, J., "Assessing the Nestle Boycott: Corporate Accountability and Human Rights," *California Management Review* 27:113-131, 1985.
 181. Pradhan, S. B., *International Pharmaceutical Marketing* (Westport, CT: Quorum Books, 1983).
 182. Redwood, H., *The Pharmaceutical Industry Trends—Problems and Achievements* (Suffolk, England: Olwicks Press, 1987).
 183. Reich, M. R., "Essential Drugs: Economics and Politics in International Health," *Health Policy* 8:39-57, 1987.
 184. Reynolds, J., *Martingale: The Extra Pharmacopoeia* (London, UK: The Pharmaceutical Press, 1989).
 185. **Rishikesh, D.**, "Extraterritoriality Versus Sovereignty in International Antitrust Jurisdiction," *World Competition* 14(3):33-66, 1991.
 186. Rosenthal, D. E., "Jurisdictional Conflicts Between Sovereign Nations," *International Lawyer* 19(2):487-503, 1985.
 187. Rowan, R., Chair, Pharmaceutical Workgroup, Interfaith Center on Corporate Responsibility, Office for Responsible Investment, Medical Mission Sisters, **Roslindale, MA**, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Aug. 26, 1992.
 188. Salmon, C.-L., "Milking Deadly Dollars From the Third World," *Business and Society Review* 68:43-49, 1989.
 189. Schmidt, H. R., "The **Extraterritorial** Application of the United States Antitrust Laws," *Journal of Law and Commerce* 5:321-345, 1985.
 190. Schnieder, B., "Drug Regulation in the Federal Republic of Germany," *International Journal of Technology Assessment* 2:643-650, 1986.
 191. **SCRIP, SCRIP Pharmaceutical League Tables** (Surrey, UK: PJB Publications, Ltd., 1989).
 192. SCRIP World Pharmaceutical News, "U.S. Companies Support PMA Brazil Action," *SCRIP World Pharmaceutical News* 1243:18, 1987.
 193. **SCRIP World Pharmaceutical News, Far East Pharmaceutical Markets—Risks and Opportunities** (Richmond, UK: PJB Publications, 1988).
 194. SCRIP World Pharmaceutical News, "WHO's pINN's List No. 60," *SCRIP World Pharmaceutical News* 1406:26, 1989.
 195. **SCRIP World Pharmaceutical News**, "Future Ad Complaints to **IFPMA**," *SCRIP World Pharmaceutical News* 1456:19, 1989.
 196. SCRIP World Pharmaceutical News, "**IFPMA** Asked to Adopt Ethical Criteria," *SCRIP World Pharmaceutical News*, 1478:22, 1990.
 197. SCRIP World Pharmaceutical News, "New Brazilian Health System," *SCRIP World Pharmaceutical News* 1536:23, 1990.
 198. SCRIP World Pharmaceutical News, "Top Companies in 1989/1990," *SCRIP World Pharmaceutical News* 1555:14, 1990.
 199. **SCRIP World Pharmaceutical News**, "MaLAM on Company Response s," *SCRIP World Pharmaceutical News* 1591 :20, 1991.
 200. SCRIP World Pharmaceutical News, "African Reliance on **Pharma** Imports," *SCRIP World Pharmaceutical News*, 1652:18, 1991.

201. SCRIP World Pharmaceutical News, "Pharma Ads Lack Important Data," *SCRIP World Pharmaceutical News*, 1687:18, 1992.
202. Serradell, J., and Galle, B., "Physicians Knowledge of Unlabeled Drug Use," typescript submitted for publication 1989, cited in reference 203.
203. Serradell, J., and Patwell, J.T., "Unlabeled Drug Use Patterns in a Contemporary Outpatient Setting," *Journal of Pharmacoepidemiology* 2(2):19-43, 1991.
204. Seymour, B., "Illicit Payments in International Business: National Legislation, International Codes of Conduct, and the Proposed United Nations Convention," *Legal Problems of Codes of Conduct for Multinational Enterprises*, Horn, N. (ed.) (The Netherlands: Kluwer-Deventer, 1980).
205. Sharrock, D. B., President, Merrell-Dow Pharmaceuticals, U. S. A., Statement, *Pharmaceutical Export Amendments of 1986*, hearing before the Committee on Labor and Human Resources, U.S. Senate, June 28, 1984, Serial Number 99-225 (Washington, DC: Government Printing Office, 1986).
206. Silver, L. D., "Drugs in Brazil: Background Paper for the Office of Technology Assessment Study on Drug Labeling in Developing and Newly Industrialized Countries," contract report prepared for the Office of Technology Assessment, Washington, DC, March 1990.
207. Silver, L.D., Visiting Professor, National School of Public Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Aug. 18, 1992,
208. Silverman, M., *The Drugging of the Americas* (Berkeley, CA: University of California Press, 1976).
209. Silverman, M., and Lee, P. R., *Pills, Profits and Politics* (Berkeley, CA: University of California Press, 1974).
210. Silverman, M., Lee, P. R., and Lydecker, M., *Prescriptions for Death-The Drugging of the Third World* (Berkeley, CA: University of California Press, 1982).
211. Silverman, M., Lee, P. R., and Lydecker, M., "Drug Promotion: The Third World Revisited," *International Journal of Health Services* 16(4):659-667, 1986.
212. Silverman, M., Lee, P. R., and Lydecker, M., *Bad Medicine: The Prescription Drug Industry in the Third World* (Stanford, CA: Stanford University Press, 1992).
213. Stepita-Klauco, M., Manager, Corporate Labeling, Regulatory Affairs and Corporate Compliance, Syntex Corp., Washington, DC, personal communication, Oct. 10, 1991.
214. Stem, L., and Sirnon, P., "French Drug Policy," *International Journal of Technology Assessment* 2:637-642, 1986.
215. Temple, R., Acting Director, Office of Drug Research and Review, Center for Drugs and Biologics, "Reevaluation of Marketed Drugs: The DESI Program," unpublished paper presented at 3d International Conference of Drug Regulatory Authorities, Stockholm, Sweden, June 11-14, 1984.
216. Thai Drug Study Group, *Thai Consumers v. Drug Situation*, Drug Exhibition on "Thai Consumers & Drug Situation," presented by Drug Study Group, 11th IOCU World Congress, Dec. 9-14, 1984, Bangkok, Thailand.
217. Thompson, D. F., and Heflin, N. R., "Frequency and Appropriateness of Drug Prescribing for Unlabeled Uses in Pediatric Patients," *American Journal of Hospital Pharmacy* 44:792-794, 1987.
218. Thompson, R. B., "United States Jurisdiction over Foreign Subsidiaries: Corporate and International Law Aspects," *Law & Policy in International Business* 15:319-400, 1983.
219. *Timberlane Lumber Co. v. Bank of America N.T. & S.A. (Timberland)*, 549 F.2d. 597 (9th Cir. 1976),
220. Tittmann, H. H., "Extraterritorial Application to U.S. Export Control Laws on Foreign Subsidiaries of U.S. Corporations: An American Lawyer's View From Europe," *International Lawyer* 16(4):730-737, 1982.
221. *Todhunter-Mitchell & Co., Ltd. v. Anheuser-Busch, inc.*, 383 F. Supp. 586, 587 (E.D. Pa. 1974).
222. Troetel, W.M., Winship, M. D., Guarino, R. A., "Abbreviated and Supplemental New Drug Applications," *New Drug Approval Process Clinical and Regulatory Management* (New York, NY: Marcel Dekker, Inc., 1987).
223. United Nations Centre on Translational Corporations, *Translational Corporations in the Pharmaceutical Industry of Developing Countries* (New York, NY: United Nations, 1984).
224. United Nations Centre on Translational Corporations, "The U.N. Code of Conduct on Translational Corporations," *U. N. C.T. C. Current Studies* 4(A), 1988.

225. United Nations **Centre** on Translational Corporations, "The New Code Environment," *U.N.C.T.C. Current Studies* 16(A), 1990.
226. United Nations **Centre** on Translational Corporations, *The CTC Reporter* 29:5, 1990.
227. United Nations **Centre** on Translational Corporations, Proposed Text of the Draft Code of Conduct on Translational Corporations, Paragraphs 67, 69-70 *reprinted in* Annex to United Nations Economic and Social Council, *Development and International Economic Co-Operation: Translational Corporations*, U.N. Dec. E/1990/94 (New York, NY: United Nations, June 12, 1990).
228. *United States v. Aluminum Co. of America (ALCOA)*, 148 F.2d 416,443 (2d. Cir. 1945).
229. *United States v. Rodriguez*, 182 F. Supp. 479, 491 (S.D. Cal. 1960),
230. *United States v. Topco Associates*, 405 U.S. 596, 610 (1972).
231. U.S. Congress, House of Representatives, "Unlawful Corporate Payments Act of 1977," *Congressional Record* 123(28): H36303-H36308, 1977.
232. U.S. Congress, House of Representatives, *Joint Explanatory Statement of the Committee of Conference: Corporate Bribery of Foreign Officials* Conference Report, H. **Rpt.** 95-831, *reprinted in U.S. Code and Congressional Administrative News*, 95th Cong., 1st Sess. (St. Paul, MN: West Publishing Co., 1978).
233. U.S. Congress, House of Representatives, Committee on Interstate and Foreign Commerce, *Unlawful Corporate Payments Act of 1977*, H. **Rpt.** 95-640, (Washington, DC: U.S. Government Printing Office, 1978).
234. U.S. Congress, House of Representatives, Committee on the Judiciary, *Foreign Trade Antitrust Improvements Act of 1982*, H. **Rpt.** 97-686, *reprinted in U.S. Congressional News and Administrative Service* (St. Paul, MN: West Publishing Co., 1982).
235. U.S. Congress, House of Representatives, Committee on Science and Technology, **Subcommittee** on Science, Research and Technology, *The Food and Drug Administration's Process for Approving New Drugs*, Committee Print (Washington, DC: U.S. Government Printing Office, 1980).
236. U.S. Congress, Library of Congress, Congressional Research Service, "U.S. Foreign Direct Investment Policy: Response to Foreign Government Investment Barriers and Distortions," prepared by R. Ahearn (Washington, DC: U.S. Government Printing Office, 1982).
237. U.S. Congress, Library of Congress, Congressional Research Service, "The U.S. Foreign Tax Credit: Provisions, Effects and Issues," prepared by **D.L. Brumbaugh** (Washington, DC: U.S. Government Printing Office, 1983).
238. U.S. Congress, Library of Congress, Congressional Research Service, "Foreign Direct Investment: Why Companies Invest Abroad," prepared by **J.K. Jackson** (Washington, DC: U.S. Government Printing Office, 1990).
239. U.S. Congress, Office of Technology Assessment, *Government Policies and Pharmaceutical Research and Development* (Washington, DC: U.S. Government Printing Office, forthcoming).
240. U.S. Congress, Senate, Committee on Banking, Housing And Urban Affairs, *Report on Questionable and Illegal Corporate Payments and Practices*, prepared by the Securities and Exchange Committee, Committee Print (Washington, DC: U.S. Government Printing Office, 1976).
241. U.S. Congress, Senate, Committee on Labor and Human Resources, *Pharmaceutical Export Amendments of 1986*, S. **Rpt.** 99-225, *reprinted in U.S. Code and Congressional Administrative News* 6:6298-6335 (St. Paul, MN: West Publishing Co., 1986).
242. U.S. Department of Commerce, International Trade Administration, *A Competitive Assessment of the U.S. Pharmaceutical Industry* (Washington, DC: U.S. Government Printing Office, 1984).
243. U.S. Department of Commerce, International Trade Commission, *U.S. Industrial Outlook '92* (Washington, DC: U.S. Government Printing Office, 1992).
244. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, "From Test Tube to Patient: New Drug Development in the United States," *FDA Consumer Special Report*, HHS Pub. No. (FDA) 90-3168 (Washington, DC: U.S. Government Printing Office, 1988).
245. U.S. Department of Health and Human Services, Public Health Service, Food and Drug Administration, Office of Drug Evaluation, *Statistical Report* (Washington, DC: U.S. Government Printing Office, 1989).
246. U.S. Department of Health and Human Services, Public Health Service, Food and Drug **Ad-**

- ministration, Division of OTC Drug Evaluation, "Milestones of OTC Drug Review Documents-July 15, 1992" (Rockville, MD: Food and Drug Administration, 1991).
247. U.S. Pharmacopeial Convention, Inc., *USP Drug Information for the Health Care Professional* (Rockville, MD: U.S. Pharmacopeial Convention, Inc., 1988, 1989, 1990, 1991).
248. Uzzell, J. K., and Meyer, G. F., "Learning Lessons at the School of NDA Submissions," *Pharmaceutical Executive* 10(6):82, 84, 86, 1990.
249. Vidal, L., *Dictionnaire Vidal* (Paris, France: Office de Vulgarisation Pharmaceutique, 1992).
250. Virginia Journal of International Law, "Innocents Abroad: Infant Food Technology at the Law's Frontier," *Virginia Journal of International Law* 20(3):617-667, 1980.
251. Virginia Journal of International Law, "International Regulation of Pharmaceuticals: The Role of the World Health Organization," *Virginia Journal of International Law* 23:331-361, 1983.
52. Voisin, E. M., Cheix, F., Champion, M. D., et al., "New Drug Registration in France," *Food Drug Cosmetic Law Journal* 46:707-725, 1992.
253. Von Mehren, R. B., and Gold, M. E., "Multinational Corporations: Conflicts and Controls," *Stanford Journal of International Studies* 11:1-41, 1976.
254. Wade, V. A., Mansfield, P. R., and McDonald, P. J., "Drug Companies' Evidence to Justify Advertising," *Lancet* 2(8674):1261-1264, 1989.
255. Wallace, C. D., *Foreign Direct Investment in the 1990s—A New Climate in the Third World* (Dordrecht, The Netherlands: Martinus Nijhoff Publishers, 1990).
256. Wallace, D., Jr., *International Regulation of Multinational Corporations* (New York: Praeger Publishers, 1976).
257. Wehrli, A., "Protection of International Nonproprietary Names (INN) (Generic Names)," presented at *2nd International Conference on Pharmacopoeias* (Bologna, Italy: Editrice Compositio, 1987).
258. Wehrli, A., "WHO's Role in Drug Information," unpublished paper presented at FIP Congress, Amsterdam, The Netherlands, 1987.
259. Wehrli, A., Chief, Regulatory Support, Division of Drug Management and Policies, World Health Organization, Geneva, Switzerland, letter to the Office of Technology Assessment, U.S. Congress, Washington, DC, Aug. 31, 1992.
260. Wergroep Medisch Ontwikkelings Samenwerking (WEMOS), *Organon and Anabolic Steroids* (Amsterdam, The Netherlands: WEMOS Pharma Group, 1987).
261. Wergroep Medisch Ontwikkelings Samenwerking (WEMOS), *A Question of Control* (Amsterdam, The Netherlands: HAI, 1991).
262. Wilkes, M. S., Doblin, B. H., and Shapiro, M. F., "Pharmaceutical Advertisements in Leading Medical Journals: Experts' Assessments," *Annals of Internal Medicine* 116:912-919, 1992.
263. World Health Assembly, *WHO's Revised Drug Strategy* WHA 39/1986 /Rec/1, Annex 5 (Geneva, Switzerland: World Health Assembly, Feb. 10, 1986).
264. World Health Assembly, *Ethical Criteria for Medicinal Drug Promotion* WHA41.17 (Geneva, Switzerland: World Health Assembly, May 13, 1988).
- World Health Assembly, *WHO Ethical Criteria for Medicinal Drug Promotion* WHA 45.13 (Geneva, Switzerland: World Health Assembly, May 14, 1992).
265. World Health Assembly, *WHO Ethical Criteria for Medicinal Drug Promotion* WHA 45.30 (Geneva, Switzerland: World Health Assembly, May 14, 1992).
266. World Health Assembly, *Proposed Guidelines on the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce* WHA 45.29 (Geneva, Switzerland: World Health Assembly, May 14, 1992).
267. World Health Organization, *Ethical and Scientific Criteria for Pharmaceutical Advertising* (Geneva, Switzerland: World Health Organization, 1968).
268. World Health Organization, *International Code of Marketing of Breast-Milk Substitutes*, WHA34.22 (Geneva, Switzerland: World Health Organization, May 21, 1981).
269. World Health Organization, *International Code of Marketing of Breast-Milk Substitutes* (Geneva, Switzerland: Reggiani/Presses Centrale, 1981).
270. World Health Organization, *Handbook of Resolutions and Decisions of the World Health Assembly & the Executive Board* (4th ed.), W.H.A. Res. 31.32 (Geneva, Switzerland: World Health Organization, 1978) cited in reference 251.
271. World Health Organization, *The Use of Essential Drugs: Second Report of the WHO Expert Committee on the Use of Essential Drugs* WHO

- Technical Report Series, No. 722 (Geneva, Switzerland: World Health Organization, 1985).
272. World Health Organization, *Review of Drug Programme in Thailand: Report of a WHO Mission, 24 November-12 December 1986* (Geneva, Switzerland: World Health Organization, 1986).
 273. World Health Organization, *Report on the WHO Survey on "Ethical Criteria for Drug Promotion: WHO's Ethical and Scientific Criteria for Pharmaceutical Advertising"* Annex 3, DGO/ETHCDP/87.3, WHA21.41 (Geneva, Switzerland: World Health Organization, 1987).
 274. World Health Organization, *Summary of Progress in the WHO Action Programme on Essential Drugs and Vaccines* (Geneva, Switzerland: World Health Organization, 1987).
 275. World Health Organization, *The Rational Use of Drugs, Report of the Conference of Experts, Nairobi* (Geneva, Switzerland: World Health Organization, 1987).
 276. World Health Organization, *Guidelines for Developing National Drug Policies* (Geneva, Switzerland: World Health Organization, 1988).
 277. World Health Organization, *Rational Use of Drugs (Review of WHO's Revised Drug Strategy) Report of the Director General—Corrigendum A41/17 Corr.1*. Provisional Agenda Item 23 (Geneva, Switzerland: World Health Organization, Apr. 20, 1988).
 278. World Health Organization, Expert Committee on Pharmaceutical Specifications for Pharmaceutical Preparations, *Thirty-First Report: Guiding Principles for Small National Drug Regulatory Authorities Annex 6, TRS no. 790* (Geneva, Switzerland: World Health Organization, 1988).
 279. World Health Organization, *World Drug Situation* (Geneva, Switzerland: World Health Organization, 1988).
 280. World Health Organization, *WHO Model Prescribing Information: Drugs Used in Anesthesia* (Geneva, Switzerland: World Health Organization, 1989).
 281. World Health Organization, *The International Code of Marketing of Breast-Milk Substitutes: Synthesis of Reports on Action Taken (1981-1990) WHO/MCH/NUT/90.1* (Geneva, Switzerland: World Health Organization, 1990).
 282. World Health Organization, *WHO Model Prescribing Information: Drugs Used in Parasitic Diseases* (Geneva, Switzerland: World Health Organization, 1990).
 283. World Health Organization, *WHO Model Prescribing Information: Drugs Used in Parkinsonism*, typescript (Geneva, Switzerland: World Health Organization, 1990).
 284. World Health Organization, *Drugs Used in Mycobacterial Diseases* (Geneva, Switzerland: World Health Organization, 1991).
 285. World Health Organization, Progress Report by the Director-General, *Implementation of WHO's Revised Drug Strategy: Safety and Efficacy of Pharmaceutical Products A45/13* (Geneva, Switzerland: World Health Organization, 1992).
 286. World Health Organization, Action Programme on Essential Drugs, *Report for the Biennium 1990-1991 DAP/MAC(4)/92.4* (Geneva, Switzerland: World Health Organization, 1992).
 287. World Health Organization, *Revised Drug Strategy: Safety and Efficacy of Pharmaceutical Products* (Geneva, Switzerland: World Health Organization, 1992).
 288. World Health Organization, *WHO Model Prescribing Information: Drugs in Epilepsy*, typescript (Geneva, Switzerland: World Health Organization, undated).
 289. World Health Organization, *WHO Model Prescribing Information: Drugs Used in Superficial Fungal Infections*, typescript (Geneva, Switzerland: World Health Organization, undated).
 290. World Health Organization Collaborating Centre for International Drug Monitoring, *WHO International Drug Monitoring Programme (Uppsala, Sweden: World Health Organization Collaborating Centre for International Drug Monitoring, 1991)*.
 291. Young, S., Deputy Director, Office of Compliance, Food and Drug Administration, Public Health Service, U.S. Department of Health and Human Services, **Rockville, MD**, personal communication, July 1, 1992.
 292. Yudkin, J. S., "Provision of Medicine in a Developing Country," *Lancet* 1(8068):810-812, 1978.
 293. Zimmerman, J. M., "Extraterritorial Application of Federal Labor Laws: Congress's Flawed Extension of the ADEA," *Cornell International Law Journal* 21:103-126, 1988.